MXPA03006071A - Preparaciones de ciclodextrina. - Google Patents

Preparaciones de ciclodextrina.

Info

Publication number
MXPA03006071A
MXPA03006071A MXPA03006071A MXPA03006071A MXPA03006071A MX PA03006071 A MXPA03006071 A MX PA03006071A MX PA03006071 A MXPA03006071 A MX PA03006071A MX PA03006071 A MXPA03006071 A MX PA03006071A MX PA03006071 A MXPA03006071 A MX PA03006071A
Authority
MX
Mexico
Prior art keywords
cyclodextrin
ebselen
aqueous solution
mixing
water
Prior art date
Application number
MXPA03006071A
Other languages
English (en)
Inventor
Suzuki Norio
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Publication of MXPA03006071A publication Critical patent/MXPA03006071A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D293/00—Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms
    • C07D293/10—Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D293/12—Selenazoles; Hydrogenated selenazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Inorganic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion puede proporcionar la siguiente que es una solucion acuosa transparente de una cantidad suficiente de ebselen y utilizable como una inyeccion. Una preparacion con base agua o solucion acuosa que comprende ebselen y ciclodextrina. Una inyeccion que comprende la solucion acuosa. Una infusion intravenosa por goteo que comprende la solucion acuosa. Un proceso para producir una solucion acuosa que contiene ebselen y ciclodextrina, que comprende disolver ebslen en un solvente organico miscible en agua mientras que por separado se disuelve una ciclodextrina en un solvente de agua, mezclar ambas soluciones, despues secar la mezcla y mezclar el producto seco resultante con un solvente de agua. Una preparacion seca que comprende ebselen y ciclodextrina. Un proceso para producir una solucion que contiene ebselen y ciclodextrina, que comprende disolver ebselen en un solvente organico miscible en agua mientras que por separado se disuelve ciclodextrina en un solvente de agua y mezclar ambas soluciones.
MXPA03006071A 2001-01-04 2001-12-17 Preparaciones de ciclodextrina. MXPA03006071A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001000247 2001-01-04
JP2001016022 2001-01-24
PCT/JP2001/011048 WO2002055076A1 (fr) 2001-01-04 2001-12-17 Preparation pharmaceutique contenant de la cyclodextrine

Publications (1)

Publication Number Publication Date
MXPA03006071A true MXPA03006071A (es) 2004-02-26

Family

ID=26607336

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03006071A MXPA03006071A (es) 2001-01-04 2001-12-17 Preparaciones de ciclodextrina.

Country Status (12)

Country Link
US (1) US20040053888A1 (es)
EP (1) EP1348432A4 (es)
JP (1) JPWO2002055076A1 (es)
KR (1) KR20030068203A (es)
CN (1) CN1492760A (es)
AR (1) AR032386A1 (es)
BR (1) BR0116658A (es)
CA (1) CA2434077A1 (es)
MX (1) MXPA03006071A (es)
NO (1) NO20033042L (es)
RU (1) RU2003119972A (es)
WO (1) WO2002055076A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058281A1 (fr) 1999-03-31 2000-10-05 Daiichi Pharmaceutical Co., Ltd. Substrats pour thioredoxine reductase
CN1853627B (zh) * 2005-04-25 2011-08-10 曾慧慧 双苯并异硒唑乙烷环糊精或环糊精衍生物包合物及其制备方法和其用途
ZA200800907B (en) 2005-07-18 2010-04-28 Bipar Sciences Inc Treatment of cancer
JP4886233B2 (ja) * 2005-07-21 2012-02-29 独立行政法人物質・材料研究機構 エブセレンの可溶化方法
CN100503647C (zh) * 2005-11-02 2009-06-24 南京师范大学 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用
PL1795183T3 (pl) * 2005-12-09 2009-12-31 Teva Pharma Wodne dyspersje i roztwory słabo rozpuszczalnych związków oraz sposoby ich wytwarzania
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
US8143447B2 (en) 2006-09-05 2012-03-27 Bipar Sciences, Inc. Treatment of cancer
WO2008030891A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
CN100411688C (zh) * 2006-09-12 2008-08-20 南京师范大学 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法
CN100486645C (zh) * 2006-09-12 2009-05-13 南京师范大学 含有环糊精紫杉醇包合物的药物组合物及其制备方法
RS52633B (en) * 2007-01-16 2013-06-28 Bipar Sciences Inc. CANCER TREATMENT FORMULATION
EP2217227B1 (en) 2007-11-12 2013-08-21 BiPar Sciences, Inc. Treatment of breast cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents
SG173198A1 (en) * 2009-02-04 2011-09-29 Bipar Sciences Inc Treatment of lung cancer with a parp inhibitor in combination with a growth factor inhibitor
GB201102248D0 (en) 2011-02-09 2011-03-23 Isis Innovation Treatment of bipolar disorder
RU2451680C1 (ru) * 2011-02-21 2012-05-27 Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" Клатратный комплекс циклодекстрина или арабиногалактана с 9-фенил-симм-октагидроселеноксантеном, способ его получения (варианты), фармацевтическая композиция и лекарственное средство
WO2015042170A1 (en) 2013-09-17 2015-03-26 Wayne State University Compositions and uses of combinations of dim-related indoles and selected anti-androgen compounds
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
US10576086B2 (en) 2015-06-12 2020-03-03 University Of Greenwich Triazine derivatives as interferon-gamma inhibitors
TWI830180B (zh) * 2017-06-30 2024-01-21 財團法人工業技術研究院 化合物之液體劑型的醫藥配方
WO2021054863A1 (ru) * 2019-09-18 2021-03-25 Рахимджан Ахметджанович РОЗИЕВ Стимулятор процессов репаративной регенерации тестикулярной ткани
WO2023240094A1 (en) * 2022-06-06 2023-12-14 Sound Pharmaceuticals Inc. Amorphous dosage form containing ebselen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01131113A (ja) * 1987-08-27 1989-05-24 Dai Ichi Seiyaku Co Ltd 脳障害治療剤
US5288734A (en) * 1988-10-29 1994-02-22 A. Nattermann & Cie Gmbh Stable parenteral solution of 2-phenyl-1.2-benzisoselenazol-3(2H)-one and process for producing the same
AU5780696A (en) * 1995-06-02 1996-12-18 Takeda Chemical Industries Ltd. Stabilized composition comprising an antiulcerative benzimid azole
CA2306465A1 (en) * 1997-11-07 1999-05-20 Daiichi Pharmaceutical Co. Ltd. Piperazine-cyclodextrin complexes
WO2000032230A1 (fr) * 1998-11-30 2000-06-08 Sankyo Company, Limited Preparations d'immunoglobuline

Also Published As

Publication number Publication date
EP1348432A4 (en) 2005-08-10
CN1492760A (zh) 2004-04-28
BR0116658A (pt) 2003-12-30
WO2002055076A1 (fr) 2002-07-18
RU2003119972A (ru) 2004-12-27
EP1348432A1 (en) 2003-10-01
NO20033042D0 (no) 2003-07-02
CA2434077A1 (en) 2002-07-18
JPWO2002055076A1 (ja) 2004-05-13
US20040053888A1 (en) 2004-03-18
AR032386A1 (es) 2003-11-05
NO20033042L (no) 2003-09-04
KR20030068203A (ko) 2003-08-19

Similar Documents

Publication Publication Date Title
MXPA03006071A (es) Preparaciones de ciclodextrina.
CN106009001B (zh) 壳聚糖气凝胶的制备方法
CA2417500A1 (en) Erbb-2 selective small molecule kinase inhibitors
DE69906269T2 (de) Wässriges verfahren zur herstellung fester paroxetin-dispersionen
WO2008043054A3 (en) Method for producing a low sodium salt composition
JP2001089503A5 (es)
DE60117873D1 (de) Verfahren zur herstellung von submikropartikel-suspensionen pharmazeutischer substanzen
TW200724745A (en) Long-term antibiotic and deodorant textile and preparation method thereof
PL1969014T3 (pl) Sposób modyfikowania skrobi
WO2006085957A3 (en) Polymeric nanocomposites and processes for making the same
WO2002022172A3 (en) Powdered/microfibrillated cellulose
KR900701251A (ko) 약제학적 피막 형성 조성물
WO2005025500A3 (en) Process for preparing water soluble diterpenes and their applications
WO2001060890A3 (fr) Procede de preparation de polyalkylenimines fonctionnalises, compositions les contenant et leur utilisations
MXPA03003533A (es) Metodo para producir una solucion que consiste en un polimero que contiene unidades azol recurrentes, soluciones producidas de acuerdo con dicho metodo y uso de las mismas.
WO2005097201A3 (fr) Complexes d’inclusions comprenant du piroxicam, une cyclodextrine et l’arginine
AR036601A1 (es) Envase hidrosoluble con colorante fluorescente en la pelicula
GB0302673D0 (en) Pharmaceutical formulations
AU2001226867A1 (en) Cosmetic compositions containing aqueous polymeric dispersions, film-forming in the absence of organic solvent
TW200513569A (en) Aqueous liquid compositions of cyclodextrine or cyclodextrine derivatives and a process using the said composition
AU2003233064A1 (en) Process for the preparation of the amorphous form of atorvastatin calcium salt
CN105061608A (zh) 荧光淀粉纳米晶及其制备方法与应用
AU2003233053A1 (en) Aqueous liquid compositions of reactive cyclodextrin derivatives and a finishing process using the said composition
DK1399138T3 (da) Fremgangsmåde til fremstilling af faste formuleringer af natrium-3-hydroxy-3-methylbutyrat
CN103012607A (zh) 一种具有高尿素吸附性的双醛多孔淀粉的制备方法